Key result
Next-generation sequencing genetically classified all 30 patients with nemaline myopathy, with NEB mutations being the most frequent (64% of families).
Why the study?
Nemaline myopathy, a structural congenital myopathy, presents significant clinical and genetic heterogeneity.
Observational (n=30)
Next-generation sequencing successfully identified the genetic basis of Nemaline myopathy in a Brazilian cohort, highlighting a high frequency of NEB mutations and significant phenotypic heterogeneity.
May aid NM genetic diagnosis in Brazilian patients; leaves open variant validation and phenotype correlations in larger cohorts.
Nemaline myopathy (NM), a structural congenital myopathy, presents a significant clinical and genetic heterogeneity. Here, we compiled molecular and clinical data of 30 Brazilian patients from 25 unrelated families. Next-generation sequencing was able to genetically classify all patients: sixteen families (64%) with mutation in NEB, five (20%) in ACTA1, two (8%) in KLHL40, and one in TPM2 (4%) and TPM3 (4%). In the NEB-related families, 25 different variants, 11 of them novel, were identified; splice site (10/25) and frame shift (9/25) mutations were the most common. Mutation c.24579 G>C was recurrent in three unrelated patients from the same region, suggesting a common ancestor. Clinically, the “typical” form was the more frequent and caused by mutations in the different NM genes. Phenotypic heterogeneity was observed among patients with mutations in the same gene. Respiratory involvement was very common and often out of proportion with limb weakness. Muscle MRI patterns showed variability within the forms and genes, which was related to the severity of the weakness. Considering the high frequency of NEB mutations and the complexity of this gene, NGS tools should be combined with CNV identification, especially in patients with a likely non-identified second mutation.
No takes yet. Share an insight, caveat, or question.
Gurgel‐Giannetti et al. (2022) conducted an observational in Nemaline myopathy (n=30). Next-generation sequencing was evaluated on Genetic classification. Next-generation sequencing genetically classified all 30 patients with nemaline myopathy, with NEB mutations being the most frequent (64% of families).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: